42.05
+6.05%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rigel Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Rigel Pharmaceuticals is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RIGL. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $294.3m and net income of $367.0m. At that date it held total assets of $513.6m and shareholders' equity of $391.5m.
We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.
TAVALISSE® (fostamatinib disodium hexahydrate) is our first FDA-approved product and is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Japan, the Republic of Korea (Korea), Canada and Israel (as TAVALISSE) for the treatment of chronic ITP in adult patients.
REZLIDHIA® (olutasidenib) is our second FDA-approved product and indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. We in-licensed REZLIDHIA from Forma Therapeutics, Inc., now Novo Nordisk (Forma), with exclusive, worldwide rights for its development, manufacturing and commercialization, pursuant to a license and transition services agreement entered in July 2022.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Nov 2000
- Employees
- 172
- Website
- rigel.com ↗
- Head office
- 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Gregg LapointeIndependent Chairman of the Board$170,254
- Mr. Raul RodriguezPresident, Chief Executive Officer, Director, since 2000$3.0m
- Mr. Dean SchornoChief Financial Officer, Executive Vice President$1.4m
- Mr. Raymond FureyExecutive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary$1.3m
- Dr. Lisa RojkjaerExecutive Vice President, Chief Medical Officer$1.1m
- Mr. David SantosExecutive Vice President, Chief Commercial Officer$1.4m
- Ms. Kamil Ali-JacksonIndependent Director$120,254
- Dr. Mark FrohlichIndependent Director
- Dr. Alison HannahIndependent Director$113,254
- Dr. Walter MoosIndependent Director$118,254
- Ms. Jane WasmanIndependent Director$125,254
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 24
- Social
- 56
- Governance
- 71
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rigel Pharmaceuticals employs 172 employees in the Health Care sector.
- TAVALISSE is an oral SYK inhibitor for immune thrombocytopenia treatment.
- Rigel has clinical programs in autoimmune hemolytic anemia and IgA nephropathy.
Weaknesses
- Rigel's IPO was on 29 November 2000 with 169 employees.
- Rigel's headquarters is in South San Francisco, California.
- Rigel has no products approved for cancer or rare diseases.
Opportunities
- Rigel's clinical programs include Phase 2 studies for fostamatinib.
- Rigel partners with BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.
- Rigel's research focuses on signaling pathways for disease mechanisms.
Threats
- Rigel's product TAVALISSE is for immune disorders only.
- Rigel's clinical programs are in Phase 2 and Phase I stages.
- Rigel has no approved products for cancer or rare diseases.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.